The Annual Congress of the European Little league Against Rheumatism.
There were two deaths reported in the tocilizumab arm; one from unexpected death and one from illicit medication overdose.. ADACTA trial: Tocilizumab far better than adalimumab in treating RA Today at EULAR 2012 Safety results were equivalent between organizations Data presented, the Annual Congress of the European Little league Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treating rheumatoid arthritis based on differ from baseline in DAS28 at week 24. The ADACTA trial, executed in 325 individuals with RA demonstrated that tocilizumab was far better than adalimumab for DAS28 remission , low disease activity and ACR20/50/70 responses . Variations between arms were also noted in favour of tocilizumab from week eight onwards in swollen and tender joint counts, erythrocyte sedimentation rate , and individual global assessment.The list of warnings was longer compared to the paragraph on how this acne medicine worked well ! Fortunately, the side effects were reported to be short-lived and would be reversible if the medicine was stopped. Nevertheless, we were concerned as isotretinoin needed to be used for at least 12 to 16 weeks. This wonder acne medicine didn’t sound so great to us. We did try to talk her out of it. She became unhappy, stating we did not know how much she had gone through, suffering with her acne problem for years.